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A B S T R A C T
Background
Vacuum and forceps assisted vaginal deliveries are reported to increase the incidence of postpartum infections and maternal readmission
to hospital compared to spontaneous vaginal delivery. Prophylactic antibiotics may be prescribed to prevent these infections. However,
the benefit of antibiotic prophylaxis for operative vaginal deliveries is still unclear. This is an update of a review last published in 2017.
Objectives
To assess the eLectiveness and safety of antibiotic prophylaxis in reducing infectious puerperal morbidities in women undergoing
operative vaginal deliveries including vacuum or forceps delivery, or both.
Search methods
For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials
Registry Platform (ICTRP) (5 July 2019), and reference lists of retrieved studies.
Selection criteria
All randomised controlled trials comparing any prophylactic antibiotic regimens with placebo or no treatment in women undergoing
vacuum or forceps deliveries were eligible. Participants were all pregnant women without evidence of infections or other indications for
antibiotics of any gestational age. Interventions were any antibiotic prophylaxis (any dosage regimen, any route of administration or at
any time during delivery or the puerperium).
Data collection and analysis
Two review authors assessed trial eligibility and risk of bias. Two review authors extracted the data independently using prepared data
extraction forms. Any discrepancies were resolved by discussion and a consensus reached through discussion with all review authors. We
assessed methodological quality of the two included studies using the GRADE approach.
Main results
Two studies, involving 3813 women undergoing either vacuum or forceps deliveries, were included. One study involving 393 women
compared the antibiotic intravenous cefotetan aNer cord clamping compared with no treatment. The other study involving 3420 women
compared a single dose of intravenous amoxicillin and clavulanic acid with placebo using 20 mL of intravenous sterile 0.9% saline.
The evidence suggests that prophylactic antibiotics reduce superficial perineal wound infection (risk ratio (RR) 0.53, 95% confidence
interval (CI) 0.40 to 0.69; women = 3420; 1 study; high-certainty evidence), deep perineal wound infection (RR 0.46, 95% CI 0.31 to 0.69;
women = 3420; 1 study; high-certainty evidence) and probably reduce wound breakdown (RR 0.52, 95% CI 0.43 to 0.63; women = 2593;
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1 study; moderate-certainty evidence). We are unclear about the eLect on organ or space perineal wound infection (RR 0.11, 95% CI
0.01 to 2.05; women = 3420; 1 study) and endometritis (average RR 0.32, 95% CI 0.04 to 2.64; 15/1907 versus 30/1906; women = 3813; 2
studies) based on low-certainty evidence with wide CIs that include no eLect. Prophylactic antibiotics probably lower serious infectious
complications (RR 0.44, 95% CI 0.22 to 0.89; women = 3420; 1 study; high-certainty evidence). They also have an important eLect on
reduction of confirmed or suspected maternal infection. The two included studies did not report on fever or urinary tract infection.
It is unclear, based on low-certainty evidence, whether prophylactic antibiotics have any impact on maternal adverse reactions (RR 2.00,
95% CI 0.18 to 22.05; women = 2593; 1 study) and maternal length of stay (MD 0.09 days, 95% CI -0.23 to 0.41; women = 393; 1 study) as the
CIs were wide and included no eLect. Prophylactic antibiotics slightly improve perineal pain and health consequences of perineal pain and
probably reduce costs. Prophylactic antibiotics did not have an important eLect on dyspareunia (diLicult or painful sexual intercourse)
or breastfeeding at six weeks. Antibiotic prophylaxis may slightly improve maternal hospital re-admission and maternal health-related
quality of life. Neonatal adverse reactions were not reported in any included trials.
Authors' conclusions
Prophylactic intravenous antibiotics are eLective in reducing infectious puerperal morbidities in terms of superficial and deep perineal
wound infection or serious infectious complications in women undergoing operative vaginal deliveries without clinical indications for
antibiotic administration aNer delivery. Prophylactic antibiotics slightly improve perineal pain and health consequences of perineal pain,
probably reduce the costs, and may slightly reduce the maternal hospital re-admission and health-related quality of life. However, the
eLect on reduction of endometritis, organ or space perineal wound infection, maternal adverse reactions and maternal length of stay is
unclear due to low-certainty evidence.
As the evidence was mainly derived from a single multi-centre study conducted in a high-income setting, future well-designed randomised
trials in other settings, particularly in low- and middle-income settings, are required to confirm the eLect of antibiotic prophylaxis for
operative vaginal delivery.
P L A I N   L A N G U A G E   S U M M A R Y
Is antibiotic prophylaxis e5ective or safe for women undergoing operative vaginal delivery?
We set out to assess from randomised controlled studies whether giving antibiotics to all women undergoing operative vaginal deliveries
prevents infections in the mother without increasing adverse outcomes in the mother and baby. Vacuum extraction or forceps are used to
deliver the baby’s head in operative vaginal deliveries.
What is the issue?
Women who undergo vacuum- or forceps-assisted vaginal births may be more likely to have an infection aNer the birth when compared
to women who experience a normal spontaneous vaginal birth. They are also more likely to be re-admitted to hospital. Women are at
increased risk of infection because of the need for routine bladder catheterisation, multiple vaginal examinations, insertion of instruments
into the vagina, and increased risk of vaginal deep cuts or tears during the operative birth. Infection appears as fever, infection of the uterus
and surrounding tissues, an infected episiotomy or vaginal tear, or urinary tract infection. These aLect the physical state of the mother and
can impact on her well-being. The infection may also enter the bloodstream and aLect the whole body.
Why is this important?
Vacuum extraction or forceps are used to shorten labour from the time when the cervix is fully opened to birth (second stage of labour),
particularly if this is long or the baby shows signs of distress. Antibiotics can be given to mothers at the time of birth to prevent or reduce
the risk of infection. However, there are still some doubts about the benefit of such antibiotics. Antibiotics can also cause adverse reactions
such as rash or diarrhoea in the mother, and may be present in breast milk so that a breastfeeding baby is exposed to them.
What evidence did we find?
We updated our search for evidence from randomised controlled studies in July 2019. We included two studies, published in 1989 and
2019. The older study was conducted in the USA and the more recent study was from a number of hospital obstetric units in the UK. A total
of 3813 women undergoing operative vaginal delivery were included. The USA study involved 393 women and compared 2 g of intravenous
cefotetan aNer cord clamping with no treatment. The other study involved 3420 women. This study compared intravenous amoxicillin and
clavulanic acid with placebo. The certainty of the evidence varied from high certainty to low, with low certainty being downgraded because
of concerns relating to imprecise results, with few events and only a single study reporting on a number of the findings.
Prophylactic antibiotics given to reduce or prevent infection halved the number of women with infected episiotomies or lacerations. These
findings included superficial and deep perineal wound infections (one study, 3420 women; high-certainty evidence) or wound breakdown
(one study, 2593 women; moderate-certainty evidence). Serious infectious complications were also reduced (one study, 3420 women; high-
certainty evidence). Due to low-certainty evidence, prophylactic antibiotics had uncertain eLects on endometritis, experienced as fever and
uterine tenderness or heavy bleeding (two studies, 3813 women; low-certainty evidence) and infected episiotomy/laceration presenting
with organ or space perineal infection (one study, 3420 women; low-certainty evidence).
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The impact on maternal adverse reactions (one study, 2593 women; low-certainty evidence) and maternal length of stay in hospital (one
study, 393 women; low-certainty evidence) was also unclear due to the low-certainty of the study. Perineal pain and health consequences
of perineal pain were slightly reduced. Prophylactic antibiotics did not have a clear eLect on pain during sex and breastfeeding at six
weeks. Maternal hospital re-admission and maternal health-related quality of life may be slightly improved. Costs were reduced with use
of prophylactic antibiotics. Neither study specifically measured fever, urinary tract infection or adverse reactions in babies.
What does this mean?
Prophylactic antibiotics into a vein are eLective in reducing ill-health caused by infections in women undergoing operative vaginal
deliveries, and who do not have clinical indications for antibiotic administration. The evidence was mainly from a single study in a high-
income country. Well-designed randomised studies in other settings are required to confirm this finding.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Any antibiotics compared to placebo or no treatment for operative vaginal delivery
Any antibiotics compared to placebo or no treatment for operative vaginal delivery
Patient or population: operative vaginal delivery
Setting: a hospital in USA and 27 obstetric units in UK
Intervention: any antibiotics
Comparison: placebo or no treatment
Anticipated absolute effects* (95% CI)Outcomes Relative ef-
fect
(95% CI) Without any
antibiotics
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(1.5 fewer to 2.6 more)





Study populationSerious infectious complications











Study populationMaternal adverse reactions











Maternal length of stay
№ of participants: 393
(1 RCT)







length of stay with an-
tibiotics was 0.09 days





*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1 We downgraded (2) levels for very serious imprecision due to wide confidence interval crossing the line of no eLect and small number of events.
2 We downgraded (1) level for serious limitation in study design due to loss to follow up for this outcome higher than 20%.
3 We downgraded (1) level for serious inconsistency due to unexplained substantial heterogeneity.
4 We downgraded (1) level for serious imprecision due to wide confidence interval.
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B A C K G R O U N D
Description of the condition
Operative vaginal delivery is the term used to describe delivery
of the fetal head assisted by either vacuum extractor or forceps.
The commonest indications for operative vaginal delivery are
prolonged second stage of labour, suspicion of immediate or
potential fetal compromise and shortening of the second stage of
labour for maternal benefit (RCOG 2011; ACOG 2015). The rates
of operative vaginal delivery reported vary by centres in diLerent
countries (Cammu 2011; Hanley 2010; Hehir 2013; Janni 2002;
Kabiru 2001; Lawani 2014; Mola 2011; Walsh 2013) with ranges from
2.1% in Papua NewGuinea (Mola 2011) to 19.2% of all births in
northern Belgium (Cammu 2011).
The risk of postpartum infection is increased aNer operative
vaginal birth because of higher rates of vaginal lacerations, routine
bladder catheterisation, multiple vaginal examinations, insertion
of instruments into the vagina and contamination (Chaim 2000;
Pranchev 1993). Instrumental deliveries require additional vaginal
examinations, a known risk factor for endometritis and febrile
morbidity (ACOG 2015; Chang 1992; Dare 1998). Insertion of
instruments and contamination is also assumed to be one of the
risks of postpartum infection because of diLiculties in adhering to
aseptic practices during delivery (Dare 1998).
Description of the intervention
Antibiotic prophylaxis is one of the methods used to reduce the risk
of postpartum infections. It has been widely studied in obstetrics
and has shown to be eLective in reducing postoperative puerperal
morbidity aNer caesarean section in a Cochrane Review (Smail
2014). However, there are still some doubts about the benefit
of prophylactic antibiotics in reducing postpartum infection aNer
operative vaginal delivery. Due to the physiological change of
gastric emptying time, plasma volume and renal function during
pregnancy, the pharmacokinetics of antibiotics diLer between
pregnant and nonpregnant women. For these reasons careful
consideration needs to be given to the types of antibiotics and
antibiotic regimens given to pregnant women for prophylactic use
(ACOG 2018).
How the intervention might work
The reported incidence of postpartum infection or endometritis
aNer operative vaginal delivery in studies varies from 3.5% to 16%
(Hagadorn-Freathy 1991; Heitmann 1989; Kabiru 2001; Williams
1991). In addition, the outcomes of readmission within 60 days
aNer delivery and maternal sepsis have been reported as increased
in incidence following the use of operative vaginal delivery in
comparison with spontaneous vaginal delivery (Acosta 2014; Liu
2005). Postpartum infection not only aLects the physical status
of the mother and prolongs hospital stay aNer birth, but also
significantly impacts on the psychological well-being of the mother
(RCOG 2011).
The most common micro-organisms in the genitourinary tract
causing postpartum morbidities such as fever, endometritis,
infected episiotomy/vaginal laceration or urinary tract infection
are Enterococci, Streptococci, Staphylococci, Gram-negative bacilli
and anaerobes (Kok 2000; Stray-Pedersen 1988). Group B
streptococcus, Enterococcus, Gardnerella vaginalis, Staphylococcus
aureus and anaerobe bacteria were usually recovered from
the cervix and endometrium among febrile postpartum women
(Eschenbach 1986). The types of antibiotics selected to be
prophylactically used should be eLective against these common
micro-organisms and include the following: ampicillin, cephazolin,
clindamycin, vancomycin, azithromycin, and the aminoglycosides
(ACOG 2018).
Why it is important to do this review
Previous studies (Janisch 1979; Rechlin 1988) have indicated that
prophylactic antibiotics may not be necessary due to the relatively
low risk of infectious morbidity, and uncertain eLect on puerperal
fever. Aseptic precautions during operative vaginal delivery may be
enough to prevent postpartum infection (Janisch 1979). In contrast,
other studies did suggest that antibiotic prophylaxis might reduce
the risk of infection aNer normal vaginal delivery and operative
vaginal delivery (Fernandez 1993; Heitmann 1989). Criscuolo 1990
suggested that the cost of prophylactic antibiotics could be much
lower compared with the cost of treating the complications of
infection related to procedures during delivery.
However, widespread use of antibiotics may contribute to
the development of antibiotic-resistant bacteria (Towers 1998;
Weinstein 1996). A study in Vietnam found that 98% of women who
gave birth vaginally received antibiotics (Ngoc 2005). The recently
reported resistance patterns of isolated strains of Escherichia
coli, Staphylococcus aureus, Enterococci , and Streptococcus
pneumoniae are concerning (ACOG 2018). In addition, antibiotics
may contaminate breast milk, as well as cause adverse reactions
such as rash or antibiotic-related diarrhoea (Dancer 2004).
There is also a concern that there may be a significantly increased
risk of third- or fourth-degree tears, severe maternal morbidity
and death, perinatal mortality and neonatal mortality in women
with operative vaginal birth compared with normal birth (Angioli
2000; Lumbiganon 2010). The incidence of third- and fourth-degree
tears reported range from 1% to 36% of all births (Boucoiran 2010;
Goldberg 2003; Johnson 2004; Nkwabong 2011; Panigrahy 2008;
Prapas 2009). The rate of perineal wound complication measured
at two weeks postpartum was found to be significantly lower with
the use of antibiotic prophylaxis; however, loss to follow-up was
high and thus these results should be interpreted with caution
(Buppasiri 2014; Duggal 2008).
Therefore, the eLectiveness of antibiotic prophylaxis for operative
vaginal delivery needs to be carefully evaluated. This is an update
of a review last published in 2017.
O B J E C T I V E S
To assess the eLectiveness and safety of antibiotic prophylaxis in
reducing infectious puerperal morbidities in women undergoing
operative vaginal deliveries including vacuum or forceps delivery,
or both.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised trials comparing any prophylactic antibiotic
regimens with placebo or no treatment in women undergoing
vacuum or forceps delivery. Cluster-trials were eligible for inclusion
Antibiotic prophylaxis for operative vaginal delivery (Review)
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as were trials presented as an Abstract if suLicient information was
reported in order to assess eligibility. Quasi-randomised and cross-
over trials were not eligible for inclusion.
Types of participants
Pregnant women without evidence of infections or other
indications for antibiotics of any gestational age undergoing
vacuum or forceps delivery for any indication.
Types of interventions
Any antibiotic prophylaxis (any dosage regimen, any route of
administration or at any time during delivery or puerperium)
compared with either placebo or no treatment.
Types of outcome measures
We considered the following clinical outcomes.
Primary outcomes
1. Fever (body temperature of 38 degrees celsius or higher)
occurring on any two occasions in the first 10 days postpartum,
exclusive of the first 24 hours
2. Infected episiotomy/perineal/vaginal laceration (oedematous,
erythematous, wound edge with pain, serosanguineous or
frankly purulent material or wound dehiscence)
3. Endometritis (fever and uterine tenderness or heavy bleeding)
4. Urinary tract infection (fever or dysuria and positive urine
culture)
5. Serious infectious complications (such as bacteraemia, systemic
infection, septic shock, septic thrombophlebitis, necrotising
fasciitis or death attributed to infection)
6. Confirmed or suspected maternal infection within six weeks
of delivery, defined by a new prescription of antibiotics for
presumed perineal wound-related infection, endometritis or
uterine infection, urinary tract infection with systemic features
or infection; confirmed systemic infection on culture; or
endometritis (non-prespecified)
Secondary outcomes
1. Maternal adverse reactions such as allergic reactions,
anaphylaxis, antibiotic-associated diarrhoea
2. Maternal length of stay
3. Perineal pain (non-prespecified)
4. Use of pain relief for perineal pain (non-prespecified)
5. Need for additional perineal care (non-prespecified)
6. Dyspareunia (diLicult or painful sexual intercourse) (non-
prespecified)
7. Breastfeeding at six weeks (non-prespecified)
8. Perineum "ever too painful or uncomfortable" to feed baby
(non-prespecified)
9. Any primary care or home visits in relation to perineum (non-
prespecified)
10.Any outpatient visit in relation to perineum (non-prespecified)
11.Maternal hospital re-admission (non-prespecified)
12.Maternal health-related quality of life (non-prespecified)
13.Costs
14.Neonatal adverse reactions such as such as jaundice, early
neonatal infection, or any infant outcomes reported
Search methods for identification of studies
The following methods section of this review was based on a
standard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
For this update, we searched Cochrane Pregnancy and Childbirth’s
Trials Register by contacting their Information Specialist (5 July
2019).
The Register is a database containing over 25,000 reports of
controlled trials in the field of pregnancy and childbirth. It
represents over 30 years of searching. For full current search
methods used to populate Pregnancy and Childbirth’s Trials
Register including the detailed search strategies for CENTRAL,
MEDLINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals plus
monthly BioMed Central email alerts.
Search results are screened by two people and the full text of
all relevant trial reports identified through the searching activities
described above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a
specific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in a more specific search set that has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies).
In addition, we searched ClinicalTrials.gov and the WHO
International Clinical Trials Registry Platform (ICTRP) for
unpublished, planned and ongoing trial reports (5 July 2019) using
the search methods detailed in Appendix 1.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Liabsuetrakul 2017.
For this update, we used the following methods. The methods
section of this review is based on a standard template used by
Cochrane Pregnancy and Childbirth.
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Selection of studies
Two review authors independently assessed for inclusion all the
potential studies identified as a result of the search strategy. We
resolved any disagreement through discussion or, if required, we
consulted the third review author.
Data extraction and management
We designed a form to extract data. For eligible studies, two review
authors extracted the data using the agreed form. We resolved
discrepancies through discussion or, if required, we consulted
the third review author. Data were entered into Review Manager
soNware (RevMan 2014) and checked for accuracy.
When information regarding any of the above was unclear, we
planned to contact authors of the original reports to provide further
details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for
each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). Any
disagreement was resolved by discussion or by involving a third
assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for the two included studies the method used to
generate the allocation sequence in suLicient detail to allow an
assessment of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random number
table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We described for the two included studies the method used
to conceal allocation to interventions prior to assignment and
assessed whether intervention allocation could have been foreseen
in advance of, or during recruitment, or changed aNer assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for the included studies the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered in advance that
studies would be at low risk of bias if they were blinded, or if
we judged that the lack of blinding unlikely to aLect results. We
assessed blinding separately for diLerent outcomes or classes of
outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for the included studies the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for diLerent
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for the two included studies, and for each outcome
or class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomised participants),
reasons for attrition or exclusion where reported, and whether
missing data were balanced across groups or were related to
outcomes. Where suLicient information was reported, or could be
supplied by the trial authors, we planned to re-include missing data
in the analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome
data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing
data imbalanced across groups; ‘as treated’ analysis done
with substantial departure of intervention received from that
assigned at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for both included studies how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the studies' pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the studies' pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
Antibiotic prophylaxis for operative vaginal delivery (Review)
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(6) Other bias (checking for bias due to problems not covered by
(1) to (5) above)
We described for both included studies any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether the included studies
were at high risk of bias, according to the criteria given in the
Handbook (Higgins 2011). With reference to (1) to (6) above, we
planned to assess the likely magnitude and direction of the bias and
whether we considered it is likely to impact on the findings. In future
updates, if more studies are included, we will explore the impact
of the level of bias through undertaking sensitivity analyses - see
Sensitivity analysis.
Assessment of the certainty of the evidence using the GRADE
approach
We assessed the certainty of the evidence using the GRADE
approach as outlined in the GRADE handbook in order to assess the
certainty of the body of evidence relating to the following outcomes
for the main comparison between any antibiotic prophylaxis (any
dosage regimen, any route of administration or at any time during
delivery or puerperium) compared with either placebo or no
treatment.
1. Fever (body temperature of 38 degrees celsius or higher)
occurring on any two occasions in the first 10 days postpartum,
exclusive of the first 24 hours
2. Infected episiotomy/perineal/vaginal laceration (oedematous,
erythematous, wound edge with pain, serosanguineous or
frankly purulent material or wound dehiscence)
3. Endometritis (fever and uterine tenderness or heavy bleeding)
4. Urinary tract infection (fever or dysuria and positive urine
culture)
5. Serious infectious complications (such as bacteraemia, septic
shock, septic thrombophlebitis, necrotising fasciitis or death
attributed to infection)
6. Maternal adverse reactions such as allergic reactions,
anaphylaxis, antibiotic-associated diarrhoea
7. Maternal length of stay
We used the GRADEpro Guideline Development Tool to import
data from Review Manager 5.3 (RevMan 2014) in order to create
a ’Summary of findings’ table. A summary of the intervention
eLect and a measure of certainty for each of the above outcomes
was produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of eLect,
imprecision, indirectness and publication bias) to assess the
certainty of the body of evidence for each outcome. The
evidence can be downgraded from 'high certainty' by one
level for serious (or by two levels for very serious) limitations,
depending on assessments for risk of bias, indirectness of evidence,
serious inconsistency, imprecision of eLect estimates or potential
publication bias.
Measures of treatment e5ect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
We used the mean diLerence if outcomes were measured in the
same way between trials. We planned to use the standardised mean
diLerence to combine trials that measured the same outcome, but
used diLerent methods.
Unit of analysis issues
Cluster-randomised trials
In future updates, if cluster-randomised trials are identified and
included, we will adjust the standard errors using the methods
described in the Handbook using an estimate of the intracluster
correlation co-eLicient (ICC) derived from the trial (if possible),
from a similar trial or from a study of a similar population. If we use
ICCs from other sources, we will report this and conduct sensitivity
analyses to investigate the eLect of variation in the ICC.
If we identify both cluster-randomised trials and individually-
randomised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the eLect of intervention and the choice of
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the eLects of the
randomisation unit.
Cross-over trials
This study design not applicable for this review.
Other unit of analysis issues
Not applicable.
Dealing with missing data
For included studies, we noted levels of attrition. In future updates,
if more eligible studies are included, the impact of including studies
with high levels of missing data in the overall assessment of
treatment eLect will be explored by using sensitivity analysis.
For all outcomes, analyses were carried out, as far as possible,
on an intention-to-treat basis, i.e. we attempted to include all
participants randomised to each group in the analyses. The
denominator for each outcome in the included study was the
number randomised minus any participants whose outcomes were
known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau2, I2 and Chi2 statistics. We regarded heterogeneity as
substantial if an I2 was greater than 30% and either a Tau2 was
greater than zero, or there was a low P value (less than 0.10)
in the Chi2 test for heterogeneity. If we identified substantial
heterogeneity (above 30%), we planned to explore it by pre-
specified subgroup analysis. If any outcome includes only one
study, the test for heterogeneity is not applicable.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis we will investigate reporting biases (such as publication
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bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager
soNware (RevMan 2014). We used fixed-eLect meta-analysis for
combining data where it is reasonable to assume that studies are
estimating the same underlying treatment eLect: i.e. where trials
are examining the same intervention, and the trials’ populations
and methods are judged suLiciently similar.
When substantial statistical heterogeneity was detected, we
considered whether the clinical or methodological heterogeneity
was influenced using subgroup or sensitivity analyses and
we used random-eLects meta-analysis to produce an overall
summary, if an average treatment eLect across trials is considered
clinically meaningful. The random-eLects summary was treated
and presented as the average of the range of treatment eLects with
95% confidence intervals, and the estimates of Tau2 and I2.
Subgroup analysis and investigation of heterogeneity
We planned to investigate the substantial heterogeneity due to
diLerent clinical characteristics among included studies using
subgroup analysis, if appropriate.
In future updates, we will carry out the following subgroup analyses
for primary outcomes.
1. Vacuum or forceps deliveries
2. DiLerent antibiotic regimens
We will assess subgroup diLerences by interaction tests available
within RevMan (RevMan 2014). We will report the results of
subgroup analyses quoting the Chi2 statistic and P value, and the
interaction test I2 value.
Sensitivity analysis
We planned to carry out sensitivity analyses to explore the eLect of
trial quality assessed by concealment of allocation, high attrition
rates, or both, with poor-quality studies being excluded from the
analyses in order to assess whether this makes any diLerence to the
overall result.
R E S U L T S
Description of studies
Results of the search
See: Figure 1.
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Figure 1.   Study flow diagram.
 
This review update includes two studies (ANODE 2019; Heitmann
1989). One of these (Heitmann 1989) was included in the previous
version of this review (Liabsuetrakul 2017). For this update, we
identified three new reports that were assessed, together with a
report of an ongoing study that had been awaiting classification in
the previous version of this review. All four reports relate to a new
trial, which has been included in this update (ANODE 2019).
Included studies
We included two studies involving a total of 3813 women, 393
women in one study (Heitmann 1989) and 3420 women in
another study (ANODE 2019). A total of seven women withdrew
consent before the intervention was given comparing prophylactic
antibiotics in women undergoing operative vaginal deliveries with
placebo or no antibiotics (ANODE 2019).
(1) Study location and settings
One study was conducted in USA (Heitmann 1989), and the other
study was conducted in 27 hospital obstetric units in the UK (ANODE
2019).
(2) Participants
A total of 3813 women in two included studies involving
1907 women undergoing operative vaginal delivery received
prophylactic antibiotics versus 1906 women with no treatment or
placebo. One trial involved 393 women, of which 43.2% delivered
by forceps and 56.8% by vacuum extraction (Heitmann 1989). The
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other trial involved 3420 women. of which 20 sets of twins were
included leading to a total of 3440 births, delivered by forceps
in 2234 (65%) and vacuum extraction in 1196 (35%), but it was
noted that less than 1% (10) were by spontaneous vaginal delivery
(ANODE 2019).
(3) Interventions
One study (Heitmann 1989) compared 2 g of intravenous cefotetan
aNer cord clamping (n = 192) with no treatment (n = 201). The
other study (ANODE 2019) compared intravenous amoxicillin and
clavulanic acid (1 g amoxicillin and 200 mg clavulanic acid) as soon
as possible and no more than six hours aNer giving birth (n = 1715)
with placebo using 20 mL of intravenous sterile 0·9% saline within
the same timeframe (n = 1705).
(4) Outcomes
One study reported the outcomes of endomyometritis and
maternal length of stay (Heitmann 1989). The other study (ANODE
2019) measured confirmed or suspected maternal infection,
confirmed systemic infection on culture or endometritis as primary
outcomes, and systemic sepsis, perineal wound infection, perineal
pain, use of pain relief, hospital bed stay until discharge, need
for additional perineal care, dyspareunia, breastfeeding at six
weeks, perineum "ever too painful or uncomfortable" to feed
baby, maternal health-related quality of life, breastfeeding, wound
breakdown, intervention side-eLects, healthcare resource use
and costs, or adverse events as secondary outcomes. Perineal
wound infections in terms of superficial incisional infection,
deep incisional infection, or organ or space infection and wound
breakdown were reported in ANODE 2019, which were considered
as the infected episiotomy/perineal/vaginal laceration in this
review. The measurement or scale used to assess perineal pain and
perineum "ever too painful or uncomfortable" to feed baby was not
described in the trial. However, in the trial protocol (Knight 2018), it
was mentioned that pain was measured by the standard questions
developed for the HOOP study (McCandlish 1998) and the PREVIEW
study (Dudley 2017) where pain was rated as none/mild/moderate/
severe.
The definitions of endomyometritis in Heitmann 1989 were as
same as that of endometritis in ANODE 2019. Both studies did not
specifically measure fever, urinary tract infection (fever or dysuria
and positive urine culture) or neonatal adverse reactions.
(5) Dates of study, funding sources and declarations of interest
Dates when the studies were conducted were reported as:
September 1986 to February 1989 (Heitmann 1989) and 13 March
2016 to 13 June 2018 (ANODE 2019).
Funding sources and declarations of interest among primary
researchers were reported in one included study (ANODE 2019) and
could not be identified in the other included study (Heitmann 1989).
For details of the two included trials, see the Characteristics of
included studies table.
Excluded studies
One study was excluded (De Meeus 1991). The study was only
available as an abstract and there was insuLicient information in
order to assess fully for eligibility. We had contacted the authors for
further information. For further details of the excluded study, see
the Characteristics of excluded studies table.
Risk of bias in included studies
According to the 'Risk of bias' tool, one study had unclear risk of
bias overall (Heitmann 1989) and another study showed a low risk
of bias overall (ANODE 2019).
Details of the two included studies are in the Characteristics of
included studies table. Each risk of bias domain in summarised in
Figure 2 and Figure 3.
 
Figure 2.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
Heitmann 1989 used a randomisation table to generate allocation
sequence, but did not report concealment of randomisation. There
were more vacuum deliveries than forceps deliveries but they were
equally balanced between the two groups (vacuum rate was 57% in
the cefotetan group and 59% in the no treatment group).
ANODE 2019 used permuted blocks of variable size for random
sequence generation and the randomisation list was concealed by a
designated independent trial programmer and sealed, sequentially
numbered, indistinguishable packs containing the prepared drug
or placebo.
Blinding
There were no details of the blinding of intervention to either
women or clinicians as well as the outcome measurements in one
study (Heitmann 1989). It could be assumed that it was not blinded
because the comparison was no treatment. However, the main
outcome was objectively measured so it was unlikely to have been
influenced by lack of blinding (Heitmann 1989).
We assessed that the method of ANODE 2019 study for blinding
of participant, caregiver and outcome assessors was of low risk of
bias.
Incomplete outcome data
The number of samples given at intervention was the same as
those at outcome measure; however, the intention-to-treat analysis
was not clearly described in Heitmann 1989 For ANODE 2019,
the number of primary outcomes were complete but secondary
outcomes showed 24% loss to follow-up; however, it was balanced
between both groups thus it was assessed as being of low risk of
bias.
Selective reporting
In Heitmann 1989, the study protocol was not available; therefore,
there was insuLicient information to permit judgement. Also, there
was no attempt to analyse the subgroups according to the type of
delivery (Heitmann 1989). Outcomes in the study of ANODE 2019
were reported as defined in the protocol.
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Other potential sources of bias
Both studies appeared to be free of other sources of bias.
E5ects of interventions
See: Summary of findings for the main comparison Any
antibiotics compared to placebo or no treatment for operative
vaginal delivery
Two studies, involving 3813 women undergoing either vacuum or
forceps deliveries, were included. One study involving 393 women
was judged as unclear risk of bias in most domains comparing
the antibiotic intravenous cefotetan aNer cord clamping compared
with no treatment (Heitmann 1989). The other study involving
3420 women had low risk of bias comparing a single dose of
intravenous amoxicillin and clavulanic acid with placebo using 20
mL of intravenous sterile 0.9% saline (ANODE 2019).
Primary outcome
Prophylactic antibiotics reduce infected episiotomy/laceration
presenting with superficial perineal wound infection (risk ratio (RR)
0.53, 95% confidence interval (CI) 0.40 to 0.69; women = 3420; 1
study; high-certainty evidence; Analysis 1.1), deep perineal wound
infection (RR 0.46, 95% CI 0.31 to 0.69; women = 3420; 1 study; high-
certainty evidence; Analysis 1.2), and wound breakdown (RR 0.52,
95% CI 0.43 to 0.63; women = 2593; 1 study; moderate-certainty
evidence; Analysis 1.4). We are unclear of the eLect on infected
episiotomy/laceration presenting with organ or space infection (RR
0.11, 95% CI 0.01 to 2.05; women = 3420; 1 study; low-certainty
evidence; Analysis 1.3) or on endometritis (average RR 0.32, 95%
CI 0.04 to 2.64; 15/1907 versus 30/1906; women = 3813; 2 studies;
random-eLects model; I2 = 58%; low-certainty evidence; Analysis
1.5) because the certainty of the evidence was low and the CIs
were wide and included no eLect. We could not perform subgroup
or sensitivity analyses of endometritis because only two studies
were included. Prophylactic antibiotics also probably lower serious
infectious complications (RR 0.44, 95% CI 0.22 to 0.89; women =
3420; 1 study; high-certainty evidence; Analysis 1.6). Prophylactic
antibiotics have an important eLect on reduction of confirmed
or suspected maternal infection (Analysis 1.7). The two included
studies did not report fever or urinary tract infection.
Six primary outcomes were assessed as being of low- to high-
certainty evidence according to GRADE. High-certainty evidence on
superficial or deep perineal wound infection and serious infectious
complications were shown.
Secondary outcomes
It is unclear whether antibiotics have any impact on maternal
adverse reactions (RR 2.00, 95% CI 0.18 to 22.05; women =
2593; 1 study; low-certainty evidence; Analysis 1.8) and maternal
length of stay (MD 0.09 days, 95% CI -0.23 to 0.41; women =
393; 1 study; low-certainty evidence; Analysis 1.9), because the
results for both of these were based on low-certainty evidence
with confidence intervals that included both benefit and harm.
Secondary outcomes, not prespecified in the protocol, were
perineal pain (Analysis 1.10), use of pain relief for perineal pain
(Analysis 1.11), need for additional perineal care (Analysis 1.12),
dyspareunia (Analysis 1.13), breastfeeding at six weeks (Analysis
1.14), perineum "ever too painful or uncomfortable" to feed
baby (Analysis 1.15), any primary care or home visits in relation
to perineum (Analysis 1.16), any outpatient visit in relation to
perineum (Analysis 1.17), maternal hospital re-admission (Analysis
1.18), maternal health-related quality of life (Analysis 1.19) and
costs (Analysis 1.20). Prophylactic antibiotics slightly improve
perineal pain and health consequences of perineal pain, probably
reduce the costs, and may slightly reduce the maternal hospital
re-admission and health-related quality of life. Neonatal adverse
reactions were not reported in any included trials.
Two outcomes, maternal adverse reactions and maternal length of
stay, were assessed as being of low certainty according to GRADE.
The reasons for downgrading the certainty of the evidence were
because of very serious imprecision due to wide CIs crossing the
line of no eLect, a small number of events and serious limitations
in study design with many domains being at unclear risk of bias.
D I S C U S S I O N
Summary of main results
Two studies, involving 3813 women undergoing either vacuum
or forceps deliveries, were included. The studies compared the
prophylactic antibiotics with intravenous cefotetan aNer cord
clamping or a single dose of amoxicillin and clavulanic acid aNer
giving birth compared with no treatment or placebo. One study
published in 1989 reported only two out of the nine outcomes
specified in this review. One recent study published in 2019
reported almost all outcomes specified, except fever, urinary tract
infection and neonatal adverse reactions. In addition, perineal
pain and its health consequences due to perineal pain, maternal
hospital re-admission, and health-related quality of life, which were
not prespecified in the protocol, were also reported.
Prophylactic antibiotics reduce infected episiotomy/laceration
presenting with superficial or deep perineal wound infection and
wound breakdown with high-certainty and moderate-certainty
evidence, respectively. We are unclear about the eLect of
prophylactic antibiotics on endometritis or organ or space
perineal wound infection due to low-certainty evidence. Antibiotic
prophylaxis probably lowers serious infectious complications with
high-certainty evidence and has an important eLect on reduction
of confirmed or suspected maternal infection. The two included
studies did not report on fever or urinary tract infection. It is
unclear whether prophylactic antibiotics have any impact on
maternal adverse reactions and maternal length of stay with low-
certainty evidence, respectively. Prophylactic antibiotics slightly
improve perineal pain and health consequences of perineal pain
and probably reduce costs, and may slightly reduce the maternal
hospital re-admission and health-related quality of life. Neonatal
adverse reactions were not reported in either of the included
trials. Prophylactic antibiotics did not have an important eLect on
dyspareunia or breastfeeding at six weeks. Prophylactic antibiotics
may slightly reduce maternal hospital re-admission and health-
related quality of life.
Overall completeness and applicability of evidence
There were only two included studies in this review (ANODE
2019; Heitmann 1989). The large multi-centre trial involving 3420
women(ANODE 2019) dominates the analyses, with only two
outcomes including data from the older, smaller trial (Heitmann
1989). The sample size of the first trial (n = 393 women) (Heitmann
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1989) was one tenth that of the large, multi-centre trial (ANODE
2019).
In a recent survey, although the evidence has been lacking to
support the use of antibiotic prophylaxis in operative vaginal
delivery, it was reported to be widely used in clinical practice
(Liabsuetrakul 2014a). From our review, there were important
eLects of prophylactic antibiotics on reduction of infected
episiotomy/laceration presenting with superficial or deep perineal
wound infection and wound breakdown. Prophylactic antibiotics
probably lower serious infectious complications. However, our
review findings have been mainly due to the findings from a
large, multi-centre trial conducted in the UK using a single dose
of amoxicillin and clavulanic acid aNer giving birth. The practice
of operative vaginal deliveries and rate of postpartum infections
are diLerent across settings (ACOG 2015). A literature review of
10 studies conducted in the USA and the UK on postpartum
infection in women undergoing operative vaginal delivery showed
the incidence of infectious morbidities varying from 0.7% to 16%,
which was higher in forceps delivery than vacuum extraction
(Mohamed-Ahmed 2019). More trials in diLerent settings where the
practice is more widespread are needed particularly in low- and
middle-income settings.
In addition, there was insuLicient information on the scale used to
assess the perineal pain in the ANODE 2019 trial. The pain results
were presented as a binary outcome (ANODE 2019), which could
be a limitation. In the trial protocol (Knight 2018), the pain tools
referred to were described in two studies (Dudley 2017; McCandlish
1998), which defined pain as none, mild, moderate and severe. It is
therefore unclear how the binary pain outcomes were calculated.
Quality of the evidence
Overall, the included studies were at low risk of bias. The certainty
of the evidence using GRADE was low- to high-certainty evidence.
The reasons for downgrading the certainty of the evidence were
due to limitations in study design, imprecision and inconsistency.
High-certainty evidence was found for prophylactic antibiotics
on reducing infected episiotomy/laceration (superficial and deep
perineal wound infection and serious infectious complications in
operative vaginal deliveries). The certainty of evidence on infected
episiotomy/laceration presenting with wound breakdown was
downgraded due to high loss to follow-up at six weeks postpartum.
We downgraded two levels for very serious imprecision due to wide
confidence intervals crossing the line of no eLect and small number
of events for infected episiotomy/laceration presenting with organ
or space perineal wound infection and maternal adverse reactions.
The certainty of evidence on endometritis was downgraded due
to inconsistency and imprecision. We downgraded the certainty of
evidence on maternal length of stay due to a small trial with unclear
risk of bias (Heitmann 1989).
Potential biases in the review process
We conducted extensive search strategies with no language
restriction and all potential studies were checked by two review
authors to prevent the reporting biases. Independently blinding
processes of study selection, assessing risk of biases, and
data extraction using clearly-defined criteria and checklists were
performed to minimise potential biases.
Agreements and disagreements with other studies or
reviews
There are no other systematic reviews on antibiotic prophylaxis for
operative vaginal delivery published. One additional randomised
controlled trial on this issue has been conducted and was published
in 2019 (ANODE 2019) and this is now included in this review.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Evidence from two studies conducted in high-income countries,
one small and one big trial, suggest that prophylactic antibiotics
have an important eLect on reduction of superficial and deep
perineal wound infection or serious infectious complications
in women undergoing operative vaginal deliveries. The eLect
of antibiotic prophylaxis is unclear on endometritis, organ or
space perineal wound infection, maternal adverse reactions and
maternal length of stay due to low-certainty evidence. Prophylactic
antibiotics slightly improve perineal pain and health consequences
of perineal pain and probably reduce costs, and may slightly reduce
the maternal hospital re-admission and health-related quality of
life.
Implications for research
Future research on antibiotic prophylaxis for operative vaginal
delivery, particularly on type of antibiotics and route or timing of
administration, is needed to clarify whether this intervention is
eLective in reducing postpartum morbidity. As the evidence was
mainly derived from a single multi-centre study conducted in a
high-income setting, trials in diLerent settings, especially in low-
and middle-income countries are required. Outcomes on fever,
urinary tract infection and neonatal adverse reactions have not
been reported in the included studies and should be considered in
future trials.
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* Indicates the major publication for the study
 
C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods A multi-centre, randomised, blinded, controlled trial carried out at 27 hospital obstetric units in the UK.
Participants 3420 women undergoing all types of operative vaginal birth at 36 weeks or greater gestation.
Women were excluded if they had any clinical indication for antibiotic administration after delivery,
third-degree or fourth-degree perineal tears, receipt of antenatal or intrapartum antibiotics with on-
going antibiotics after delivery or a known allergy to penicillin or any of the components of amoxicillin
and clavulanic acid, or who had a history of anaphylaxis to another β-lactam agent.
 
Setting: 27 hospital obstetric units in the UK; 13 March 2016, and 13 June 2018.
Interventions A single dose of intravenous amoxicillin and clavulanic acid (1 g amoxicillin and 200 mg clavulanic acid)
as soon as possible and no more than 6 hours after giving birth (n = 1715) or placebo group using 20 mL
of intravenous sterile 0.9% saline within the same timeframe (n = 1705).
Outcomes Primary outcomes were a confirmed or suspected maternal infection within 6 weeks of delivery as de-
fined as a new antibiotic prescription for a presumed perineal wound-related infection, endometritis or
uterine infection, urinary tract infection with systemic features (pyelonephritis or sepsis) or other sys-
temic infection (clinical sepsis); confirmed systemic infection on culture; or endometritis required at
least 1 of the following criteria to be met-organisms were cultured from fluid (including amniotic fluid)
or tissue from endometrium obtained during an invasive procedure or biopsy, or the woman exhibited
at least 2 of fever (> 38 degrees Celsius), abdominal pain, uterine tenderness, or purulent drainage from
uterus (with no other recognised cause for the latter 3 symptoms).
Secondary outcomes assessed within 6 weeks of delivery were: systemic sepsis, perineal wound in-
fection, perineal pain, use of pain relief, hospital bed stay until discharge, need for additional perineal
care, dyspareunia, ability to sit comfortably to feed the baby, maternal health-related quality of life,
breastfeeding, wound breakdown, intervention side effects, healthcare resource use and costs, or ad-
verse events.
Notes Dates study conducted: the trial was carried out between 13 March, 2016 and 13 June 2018.
Funding sources for the study: NIHR Health Technology Assessment programme.
Declarations of interest among primary researchers: 4 authors declared receipt of funding from NIHR
outside the submitted work. All other authors have no competing interests to declare.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Permuted blocks of variable size was used for random sequence generation.
Allocation concealment
(selection bias)
Low risk Sealed, sequentially-numbered, indistinguishable packs containing active






Low risk Women and most clinicians including research midwives and those taking con-
sent were masked to allocation either intervention or placebo.
ANODE 2019 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Midwives, nurses, or doctors collecting outcome information were masked to




Low risk Primary outcome data were complete. Secondary outcome data were incom-




Low risk Outcomes were reported as in the study protocol.




Methods Selected by randomisation table to receive treatment or no treatment; not blinded or placebo-con-
trolled.
Participants 393 women undergoing instrumental deliveries (either vacuum or forceps deliveries).
Women were excluded if they had evidence of chorioamnionitis, or other infections, or if they were al-
lergic to penicillin or cephalosporins.
Setting: University Hospital of Jacksonville, USA; September 1986 to February 1988.
Interventions 2 g of cefotetan intravenously after cord clamping (n = 192) or no treatment (n = 201).
Outcomes Endomyometritis (at least 1 rise in oral temperature greater than 38.1 degrees Celsius after the first 24
hours of delivery and uterine tenderness or foul-smelling lochia with no clinical or laboratory evidence
confirming another source of the fever).
Notes Dates study conducted: the trial was carried out between September 1986 and February 1989.
Funding sources for the study: the funding sources of an included study could not be identified.
Declarations of interest among primary researchers: not reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A randomisation table was used for random sequence generation.
Allocation concealment
(selection bias)





Unclear risk Information not clearly mentioned.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Who measured the outcome was not mentioned.
Heitmann 1989 
Antibiotic prophylaxis for operative vaginal delivery (Review)













Low risk Same number of samples at intervention given and outcome measure.
Selective reporting (re-
porting bias)
Unclear risk The study protocol was not available, so there was insufficient information to
permit judgement.
Other bias Low risk Study appeared to be free of other sources of bias.
Heitmann 1989  (Continued)
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
De Meeus 1991 Abstract only (translated). This randomised study included 200 women including, not only instru-
mental delivery but also women undergoing manual removal of placenta or uterine exploration,
or both, premature rupture of the membranes of more than 6 hours and a labour of more than 8
hours. No details of the interventions were given for either the treatment or the control groups. The
study outcomes of postpartum fever in both comparison groups were given but they were not de-
scribed for subgroups; therefore, there were no data suitable for extraction. We could not find a
published article. We have tried to contact the author but without success to date.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Any antibiotics versus placebo or no treatment





Statistical method Effect size
1 Infected episiotomy/laceration
(superficial perineal wound infec-
tion)
1 3420 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.40, 0.69]
2 Infected episiotomy/laceration
(deep perineal wound infection)
1 3420 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.31, 0.69]
3 Infected episiotomy/laceration
(organ or space infection)
1 3420 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 2.05]
4 Infected episiotomy/laceration
(wound breakdown)
1 2593 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.43, 0.63]
5 Endometritis 2 3813 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.04, 2.64]
6 Serious infectious complica-
tions
1 3420 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.22, 0.89]
7 Confirmed or suspected mater-
nal infection
1 3420 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.49, 0.69]
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Statistical method Effect size
8 Maternal adverse reactions 1 2593 Risk Ratio (M-H, Fixed, 95% CI) 2.00 [0.18, 22.05]
9 Maternal length of stay 1 393 Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.23, 0.41]
10 Perineal pain 1 2593 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.78, 0.91]
11 Use of pain relief for perineal
pain
1 2593 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.56, 0.92]
12 Need for additional perineal
care
1 2593 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.65, 0.80]
13 Dyspareunia 1 2593 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.93, 1.23]
14 Breastfeeding at 6 weeks 1 2593 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.93, 1.09]
15 Perineum "ever too painful or
uncomfortable" to feed baby
1 2593 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.56, 0.84]
16 Any primary care or home vis-
its in relation to perineum
1 2593 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.65, 0.81]
17 Any outpatient visits in rela-
tion to perineum
1 2593 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.43, 0.70]
18 Maternal hospital re-admis-
sion
1 2593 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.55, 1.03]
19 Maternal health-related quali-
ty of life
1 2593 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.00, 0.02]
20 Costs (£) 1 2593 Mean Difference (IV, Fixed, 95% CI) -52.60 [-97.26, -7.94]
 
 
Analysis 1.1.   Comparison 1 Any antibiotics versus placebo or no treatment,
Outcome 1 Infected episiotomy/laceration (superficial perineal wound infection).
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 75/1715 141/1705 100% 0.53[0.4,0.69]
   
Total (95% CI) 1715 1705 100% 0.53[0.4,0.69]
Total events: 75 (Any antibiotics), 141 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=4.59(P<0.0001)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
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Analysis 1.2.   Comparison 1 Any antibiotics versus placebo or no treatment,
Outcome 2 Infected episiotomy/laceration (deep perineal wound infection).
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 36/1715 77/1705 100% 0.46[0.31,0.69]
   
Total (95% CI) 1715 1705 100% 0.46[0.31,0.69]
Total events: 36 (Any antibiotics), 77 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=3.85(P=0)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.3.   Comparison 1 Any antibiotics versus placebo or no treatment,
Outcome 3 Infected episiotomy/laceration (organ or space infection).
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 0/1715 4/1705 100% 0.11[0.01,2.05]
   
Total (95% CI) 1715 1705 100% 0.11[0.01,2.05]
Total events: 0 (Any antibiotics), 4 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.48(P=0.14)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.4.   Comparison 1 Any antibiotics versus placebo or no
treatment, Outcome 4 Infected episiotomy/laceration (wound breakdown).
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 142/1296 272/1297 100% 0.52[0.43,0.63]
   
Total (95% CI) 1296 1297 100% 0.52[0.43,0.63]
Total events: 142 (Any antibiotics), 272 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=6.78(P<0.0001)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.5.   Comparison 1 Any antibiotics versus placebo or no treatment, Outcome 5 Endometritis.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ANODE 2019 15/1715 23/1705 68.81% 0.65[0.34,1.24]
Heitmann 1989 0/192 7/201 31.19% 0.07[0,1.21]
   
Total (95% CI) 1907 1906 100% 0.32[0.04,2.64]
Favours antibiotics 100.1 50.2 20.5 1 Favours control
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Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 15 (Any antibiotics), 30 (Control)  
Heterogeneity: Tau2=1.56; Chi2=2.4, df=1(P=0.12); I2=58.3%  
Test for overall effect: Z=1.05(P=0.29)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.6.   Comparison 1 Any antibiotics versus placebo or
no treatment, Outcome 6 Serious infectious complications.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 11/1715 25/1705 100% 0.44[0.22,0.89]
   
Total (95% CI) 1715 1705 100% 0.44[0.22,0.89]
Total events: 11 (Any antibiotics), 25 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.3(P=0.02)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.7.   Comparison 1 Any antibiotics versus placebo or no
treatment, Outcome 7 Confirmed or suspected maternal infection.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 180/1715 306/1705 100% 0.58[0.49,0.69]
   
Total (95% CI) 1715 1705 100% 0.58[0.49,0.69]
Total events: 180 (Any antibiotics), 306 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=6.13(P<0.0001)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.8.   Comparison 1 Any antibiotics versus placebo or no treatment, Outcome 8 Maternal adverse reactions.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 2/1296 1/1297 100% 2[0.18,22.05]
   
Total (95% CI) 1296 1297 100% 2[0.18,22.05]
Total events: 2 (Any antibiotics), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
Favours antibiotics 50.2 20.5 1 Favours control
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Analysis 1.9.   Comparison 1 Any antibiotics versus placebo or no treatment, Outcome 9 Maternal length of stay.
Study or subgroup Any antibiotics Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Heitmann 1989 192 2.5 (1.4) 201 2.4 (1.8) 100% 0.09[-0.23,0.41]
   
Total *** 192   201   100% 0.09[-0.23,0.41]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.55(P=0.58)  
Favours antibiotics 21-2 -1 0 Favours control
 
 
Analysis 1.10.   Comparison 1 Any antibiotics versus placebo or no treatment, Outcome 10 Perineal pain.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 592/1296 707/1297 100% 0.84[0.78,0.91]
   
Total (95% CI) 1296 1297 100% 0.84[0.78,0.91]
Total events: 592 (Any antibiotics), 707 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=4.47(P<0.0001)  
Favours antibiotics 50.2 20.5 1 Favours control
 
 
Analysis 1.11.   Comparison 1 Any antibiotics versus placebo or
no treatment, Outcome 11 Use of pain relief for perineal pain.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 99/1296 138/1297 100% 0.72[0.56,0.92]
   
Total (95% CI) 1296 1297 100% 0.72[0.56,0.92]
Total events: 99 (Any antibiotics), 138 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.64(P=0.01)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.12.   Comparison 1 Any antibiotics versus placebo or
no treatment, Outcome 12 Need for additional perineal care.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 390/1296 543/1297 100% 0.72[0.65,0.8]
   
Total (95% CI) 1296 1297 100% 0.72[0.65,0.8]
Total events: 390 (Any antibiotics), 543 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=6.17(P<0.0001)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
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Analysis 1.13.   Comparison 1 Any antibiotics versus placebo or no treatment, Outcome 13 Dyspareunia.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 299/1296 280/1297 100% 1.07[0.93,1.23]
   
Total (95% CI) 1296 1297 100% 1.07[0.93,1.23]
Total events: 299 (Any antibiotics), 280 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.91(P=0.36)  
Favours antibiotics 50.2 20.5 1 Favours control
 
 
Analysis 1.14.   Comparison 1 Any antibiotics versus placebo or no treatment, Outcome 14 Breastfeeding at 6 weeks.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 662/1296 657/1297 100% 1.01[0.93,1.09]
   
Total (95% CI) 1296 1297 100% 1.01[0.93,1.09]
Total events: 662 (Any antibiotics), 657 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.22(P=0.83)  
Favours antibiotics 50.2 20.5 1 Favours control
 
 
Analysis 1.15.   Comparison 1 Any antibiotics versus placebo or no treatment,
Outcome 15 Perineum "ever too painful or uncomfortable" to feed baby.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 136/1296 198/1297 100% 0.69[0.56,0.84]
   
Total (95% CI) 1296 1297 100% 0.69[0.56,0.84]
Total events: 136 (Any antibiotics), 198 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.6(P=0)  
Favours antibiotics 50.2 20.5 1 Favours control
 
 
Analysis 1.16.   Comparison 1 Any antibiotics versus placebo or no treatment,
Outcome 16 Any primary care or home visits in relation to perineum.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 361/1296 496/1297 100% 0.73[0.65,0.81]
   
Total (95% CI) 1296 1297 100% 0.73[0.65,0.81]
Favours antibiotics 100.1 50.2 20.5 1 Favours control
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Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 361 (Any antibiotics), 496 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=5.56(P<0.0001)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.17.   Comparison 1 Any antibiotics versus placebo or no
treatment, Outcome 17 Any outpatient visits in relation to perineum.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 95/1296 173/1297 100% 0.55[0.43,0.7]
   
Total (95% CI) 1296 1297 100% 0.55[0.43,0.7]
Total events: 95 (Any antibiotics), 173 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=4.93(P<0.0001)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.18.   Comparison 1 Any antibiotics versus placebo
or no treatment, Outcome 18 Maternal hospital re-admission.
Study or subgroup Any antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ANODE 2019 63/1296 84/1297 100% 0.75[0.55,1.03]
   
Total (95% CI) 1296 1297 100% 0.75[0.55,1.03]
Total events: 63 (Any antibiotics), 84 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.77(P=0.08)  
Favours antibiotics 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.19.   Comparison 1 Any antibiotics versus placebo or
no treatment, Outcome 19 Maternal health-related quality of life.
Study or subgroup Any antibiotics Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
ANODE 2019 1296 0.9 (0.1) 1297 0.9 (0.1) 100% 0.01[-0,0.02]
   
Total *** 1296   1297   100% 0.01[-0,0.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.95(P=0.05)  
Favours control 0.040.02-0.04 -0.02 0 Favours antibiotics
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Analysis 1.20.   Comparison 1 Any antibiotics versus placebo or no treatment, Outcome 20 Costs (£).
Study or subgroup Any antibiotics Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI






Total *** 1296   1297   100% -52.6[-97.26,-7.94]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.31(P=0.02)  
Favours antibiotics 10050-100 -50 0 Favours control
 
 
A P P E N D I C E S
Appendix 1. Search terms for ClinicalTrials.gov and ICTRP





operative AND delivery AND antibiotics
ClinicalTrials.gov
Advanced search
operative delivery | Interventional Studies | antibiotics
forceps | Interventional Studies | antibiotics
ventouse | Interventional Studies | antibiotics
vacuum extraction | Interventional Studies | antibiotics
W H A T ' S   N E W
 
Date Event Description
5 July 2019 New citation required and conclusions
have changed
Prophylactic intravenous antibiotics are probably effective in re-
ducing infectious puerperal morbidities in women undergoing
operative vaginal deliveries without clinical indications for an-
tibiotic administration after delivery. As the evidence mainly re-
sulted from one multi-centre study in a high-income country,
future well-designed randomised trials in other settings are re-
quired to confirm the review findings.
5 July 2019 New search has been performed Search Updated. Four reports of the same multi-centre study
were reviewed, including a full-text article of this study, and were
included.
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H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 3, 2004
 
Date Event Description
12 July 2017 New search has been performed Search updated and one new ongoing study identified (ANODE
2015a).
12 July 2017 New citation required but conclusions
have not changed
Conclusions remain unchanged.
31 August 2014 New citation required but conclusions
have not changed
Review updated. No new trials identified so conclusions remain
unchanged.
31 August 2014 New search has been performed Search updated, no further trials identified. Methods updated.
Please note that blinding has now been divided into two assess-
ments: 1. Blinding of participants and personnel (performance
bias); and 2. Blinding of outcome assessors (detection bias). Ta-
bles have been updated. A 'Summary of findings' table has been
incorporated for this update.
12 October 2012 Amended The Acknowledgements section has been edited.
18 July 2012 New citation required but conclusions
have not changed
No new trials identified.
18 July 2012 New search has been performed New search for trials conducted and Background updated.
31 August 2008 New search has been performed Search updated. No new studies identified.
3 April 2008 Amended Converted to new review format.
30 June 2007 New search has been performed Search updated. No new trials identified.
31 August 2005 New search has been performed Search updated. No new trials identified.
3 April 2004 Amended Substantive amendment.
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authors. For the 2008 update, TL reviewed the draN and final version of the updated review. For the 2012, 2014, and 2017 update, TL
reviewed and updated the text. For the current 2019 update, TL assessed trial eligibility and methodological quality, extracted data and
wrote the draN and final version of the updated review.
Thanapan Choobun (TC) gathered background information and commented on the draN protocol. TC assessed trial eligibility and
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the version for publication.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Methods updated to current standard PCG methods (2017).
We added in an additional search of ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP).
The primary outcome on infected episiotomy/perineal/vaginal laceration (oedematous, erythematous, wound edge with pain,
serosanguineous or frankly purulent material or wound dehiscence) prespecified in the protocol was reported in this updated review as
superficial or deep perineal incisional infection, organ or space perineal wound infection and wound breakdown as classified in a study
of ANODE 2019.
Confirmed or suspected maternal infection within six weeks of delivery, defined by a new prescription of antibiotics for presumed perineal
wound-related infection, endometritis or uterine infection, urinary tract infection with systemic features or infection; confirmed systemic
infection on culture; or endometritis (ANODE 2019), non- prespecified in the protocol was added in this update review. Since we assumed by
its definition that it included all five prespecified primary outcomes in our protocol (fever, infected episiotomy/perineal/vaginal laceration,
endometritis, urinary tract infection, and serious infectious complications), it was added in the primary outcomes, but not the outcomes
for GRADE. In addition, the secondary outcomes of this trial (perineal pain, use of pain relief for perineal pain, need for additional perineal
care, dyspareunia, breastfeeding at six weeks, perineum "ever too painful or uncomfortable" to feed baby, any primary care or home visits
in relation to perineum, any outpatient visit in relation to perineum, maternal hospital re-admission, and maternal health-related quality
of life) representing the health consequences of perineal wound infections or pain were also added in the secondary outcomes as non-
prespecified in this update review.
The contents in the sections of "Assessment of heterogeneity", "Data synthesis", "Subgroup analysis and investigation of heterogeneity",
and "Sensitivity analysis" in this update review were revised from the protocol to make more relevant and valid for the additional included
study.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Antibiotic Prophylaxis;  Endometritis  [prevention & control];  Extraction, Obstetrical  [*adverse eLects];  Obstetrical Forceps;  Puerperal
Infection  [*prevention & control];  Randomized Controlled Trials as Topic;  Vacuum Extraction, Obstetrical  [adverse eLects];  Vaginal
Diseases  [*prevention & control]
MeSH check words
Female; Humans; Pregnancy
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